We’ve rebranded some of our products, learn more ›

CODEX® is now PhenoCycler,
Phenoptics™ is now Phenolmager.

Bevacizumab improves tumor infiltration of mature dendritic cells and effector T-cells in triple-negative breast cancer patients

Authors: Boucher, Yves; Kumar, Ashwin S.; Posada, Jessica M.; Gjini, Evisa; Pfaff, Kathleen; Lipschitz, Mikel; Lako, Ana; Duda, Dan G.; Rodig, Scott J.; Hodi, F. Stephen; Jain, Rakesh K.

Online: https://www.nature.com/articles/s41698-021-00197-w

Issue: NPJ Precis Oncol. 2021 Jun 29;5(1):62.


A single dose of bevacizumab reduced the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T and CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. Our findings provide a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease.